Stay True To The Original Aspiration While Moving Up The Corporate Ladder

After graduating from Taipei Medical University with a degree in Pharmacy and self-study in business management, accounting, and marketing during his college years, Mr. Rong-Jin Lin, our honorary president, created a solid foundation of knowledge and leveraged such basis for his work in the pharmaceutical industry. President Lin was a salesperson at Bristol Myers Squibb Co. Later, he founded his pharmaceutical distribution company. Mr. Lin continues to remain passionate and professional in the pharmaceutical industry.

President Lin An Outstanding Entrepreneur With Great Leadership

In many companies, such as TTY Biopharm, PharmaEngine, Center Laboratories Inc., GLAC Biotech Co., Mycenax, Medeon and BioGend Therapeutic etc., Mr. Lin, held the top management positions and served as chairman. Mr. Lin specialized in corporate restructurings and utilizing his expertise to revamping operations with business turnaround. Moreover, President Lin reformed these companies to move ahead of the industry curves and established industry leadership with his distinctive industry foresight and perspective.

Turnaround Center Laboratories To Dominate Taiwan Oral Liquid Drugs After Joining In 1988

Established in 1959, the Center Laboratories, Inc. (hereafter refers as the Company) founded as an all-dosage form pharmaceutical company in its early days. In 1998, Mr. Lin took over the company and shifted its focus to oral liquid drug production as its main strength. With the latest technology and a wide range of liquid drug solutions, the Company became a leader in oral liquid pharmaceuticals, specializing in various types of liquid medications. Under Mr. Lin 's guidance, the Company rose to the top position in the oral liquid pharmaceutical industry in Taiwan.

A Leading Asia Pacific Professional Biotechnology Incubator Platform Since 2008

Mr. Lin again helped the Company to undergoes its second reformed after it achieved a remarkable market share of 70% within the domestic oral liquid drugs market in 2008. During the second reformed, Mr. Lin not only optimized the oral liquid product portfolio and invested in the field of psychiatric and neurological drugs, but also transformed the company into a "biotech industrial bank" to expand its operating scale. Mr. Lin also established Bioengine capital inc. and Bioengine Technology Development Inc, dedicated to biotech industry investment and incubation. The investment targets are focused on new drugs, medical materials and agricultural biotechnology fields. In 2018, the two subsidiaries under the Company focus their major investments in the following companies: Ausnutria (1717 HK, via tender offered), Jacobio (1167 HK), BioGend Therapeutics (6733 TT), Ever Supreme Bio Technology (6712 TT) and Adimmune (4142 TT) etc. In addition, the Company also assisted Mycenax (4726 TT), Medeon (6499 TT) and Lumosa Therapeutics (6535 TT) to complete their IPOs. The Company has invested in more than 20 companies globally with a total asset value of over NTD 20 billion.
 

In order to integrate resources and achieve synergy, Mr. Lin announced to launch the third transformation, evolved the company into “Professional Biotechnology Venture Holdings Group,” (also renamed as the “Center Ventures Group”; hereafter known as “the Group”), which focusing on investing and acquiring new technologies such as innovative therapies, CDMO and high-end medical devices. Post the reformed, Mr. Lin continued to lead the Center Ventures Group’s with his role changed from Chairman to President. This role changed empowered President Lin to focus on core business execution within the group and continue to seek any potential investment target or Fallen Angel globally that can serve as the next growing drivers for the Group. President Lin plans to let Lumosa Therapeutics to become one of the leading the incubation center for Novel Drugs. In addition, with NTD 1 billion investment amount on hand, President Lin and China Medical University chairman Dr. Chang-Hai Tsai together target to make Lumosa Therapeutics to become the first Taiwanese company that made into global top 50 pharmaceutical ranking company.

Corporate Vision: Incubating The Next 7-8 Unicorn Companies By 2025

Over the past years, President Lin has implemented successful turnaround strategies in many struggling companies in the Biotech industry. Lessons learned from the past experiences, President Lin realized that companies maybe position in different life cycle or differ in investment strategy may not be able to create synergy to the Group with cashflow generation. As a result, President Lin adjusted the Group’s investment strategy in 2018, that led the Group reformed into a strategic investment holding company focusing on strategic investments rather than direct financial investments. Through M&A and other investment tools, the Group can expand its core business scales by making investment in industry via vertical integration. The Group targets to incubate at least 7-8 unicorn companies with market cap exceeding NTD$ 30 billion or USD 1 billion each by 2025. In addition, under the leadership of President Lin, the Group shall continue to leverage his expertise and experiences in Biotechnology industry and M&A background to lead the way to global market.